Population bottlenecks caused by stark population loss due to illness or habitat destruction caused mammals' disease immunity ...
Dementia is a condition that results in progressive memory or thinking problems. It's now the most common cause of death in ...
The FDA has issued a Complete Response Letter to Scholar Rock regarding the BLA for apitegromab for the treatment of spinal muscular atrophy.
The FDA has issued a Complete Response Letter to Scholar Rock regarding the BLA for apitegromab for the treatment of spinal muscular atrophy.
The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...
Biomedical research agency's new organoid modelling centre will address reproducibility concerns with AI, robotics and human ...
An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, ...
MedPage Today on MSN
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups
The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared ...
UPPSALA, Sweden, Sept. 30, 2025 /PRNewswire/ -- Navinci today announced the launch of the Naveni ® Plex Omni Service, a new offering that provides researchers with advanced access to spatial ...
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...
A new study suggests that the blood-brain barrier (BBB) remains intact in a widely used mouse model of Alzheimer’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback